Abstract
An ongoing dispute in the nutrition field is whether dietary cholesterol contributes significantly to elevated serum cholesterol and to atherosclerotic disease. Carefully controlled metabolic studies have shown that high-cholesterol intakes cause moderate increases in serum cholesterol levels. It is been difficult to verify this in population studies because of confounding factors. Nonetheless, meta-analysis of controlled studies documents a cholesterol-raising action of dietary cholesterol. Most of this effect occurs in low-density lipoproteins (LDLs), but the cholesterol content of other lipoproteins can be increased as well. Moreover, population studies strongly suggest that dietary cholesterol is atherogenic beyond any rise in LDL concentrations. It must be emphasized that dietary cholesterol is only one of several dietary factors influencing serum cholesterol levels. Others include saturated fatty acids, trans fatty acids, soluble fiber, and total caloric intake. To achieve substantial serum cholesterol lowering, favorable changes in all of these factors must be combined. To maximize cardiovascular risk reduction, a lifetime of a healthy diet is needed. Reduced cholesterol intake is only one of several factors required to achieve such a diet. In addition, reduction of cholesterol absorption can enhance serum cholesterol lowering. This can be attained by the addition of plant sterols or plant stanols to the diet or by use of ezetimibe, a cholesterol absorption blocker. By combining dietary cholesterol reduction with other cholesterol-lowering modalities, it should be possible to substantially reduce atherosclerosis throughout life short of using cholesterol-lowering drugs that act systemically.
This is a preview of subscription content, access via your institution.
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.


References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
Anitschkow N, Chalatow S, Pelias MZ. Classics in arteriosclerosis research: on experimental cholesterin steatosis and its significance in the origin of some pathological processes. Arteriosclerosis. 1983;3:178–82.
Clarkson TB. Animal models of atherosclerosis. Adv Vet Sci Comp Med. 1972;16:151–73.
Kritchevsky D. Laboratory models for atherosclerosis. Adv Drug Res. 1974;9:41–53.
Ritskes-Hoitinga J, Beynen AC. Atherosclerosis in the rat. Artery. 1988;16:25–50.
Steinberg D. In celebration of the 100th anniversary of the lipid hypothesis of atherosclerosis. J Lipid Res. 2013;54:2946–9.
McNamara DJ. The fifty year rehabilitation of the egg. Nutrients. 2015;7:8716–22.
McNamara DJ. Dietary cholesterol, heart disease risk and cognitive dissonance. Proc Nutr Soc. 2014;73:161–6.
Keys A, Anderson JT, Grande F. Serum cholesterol response to changes in the diet: II. The effect of cholesterol in the diet. Metabolism. 1965;14:759–65.
Hegsted DM, McGandy RB, Myers ML, Stare FJ. Quantitative effects of dietary fat on serum cholesterol in man. Am J Clin Nutr. 1965;17:281–95.
Hegsted DM. Serum-cholesterol response to dietary cholesterol: a re-evaluation. Am J Clin Nutr. 1986;44:299–305.
Mattson FH, Erickson BA, Kligman AM. Effect of dietary cholesterol on serum cholesterol in man. Am J Clin Nutr. 1972;25:589–94.
Hopkins PN. Effects of dietary cholesterol on serum cholesterol: a meta-analysis and review. Am J Clin Nutr. 1992;55:1060–70.
•• Berger S, Raman G, Vishwanathan R, Jacques PF, Johnson EJ. Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr. 2015;102:276–94. Meta-analysis of 17 trials showed that high intakes of dietary cholesterol raises total serum cholesterol by about 5%.
Katan MB, Beynen AC. Characteristics of human hypo- and hyperresponders to dietary cholesterol. Am J Epidemiol. 1987;125:387–99.
Beynen AC, Katan MB. Reproducibility of the variations between humans in the response of serum cholesterol to cessation of egg consumption. Atherosclerosis. 1985;57:19–31.
Katan MB, Berns MA, Glatz JF, Knuiman JT, Nobels A, de Vries JH. Congruence of individual responsiveness to dietary cholesterol and to saturated fat in humans. J Lipid Res. 1988;29:883–92.
•• Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290:502–10. This study showed that multiple dietary changes, including reducing dietary cholesterol, can reduce serum LDL-cholesterol by 25-30%.
Crouse JR, Grundy SM. Evaluation of a continuous isotope feeding method for measurement of cholesterol absorption in man. J Lipid Res. 1978;19:967–71.
Sudhop T, Reber M, Tribble D, et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res. 2009;50:2117–23.
Grundy SM, Ahrens Jr EH, Davignon J. The interaction of cholesterol absorption and cholesterol synthesis in man. J Lipid Res. 1969;10:304–15.
Grundy SM, Ahrens Jr EH. Measurements of cholesterol turnover, synthesis, and absorption in man, carried out by isotope kinetic and sterol balance methods. J Lipid Res. 1969;10:91–107.
Quintão E, Grundy SM, Ahrens Jr EH. An evaluation of four methods for measuring cholesterol absorption by the intestine in man. J Lipid Res. 1971;12:221–32.
Quintão E, Grundy SM, Ahrens Jr EH. Effects of dietary cholesterol on the regulation of total body cholesterol in man. J Lipid Res. 1971;12:233–47.
Sedaghat A, Samuel P, Crouse JR, Ahrens Jr EH. Effects of neomycin on absorption, synthesis, and/or flux of cholesterol in man. J Clin Invest. 1975;55:12–21.
Samuel P, Crouse JR, Ahrens Jr EH. Evaluation of an isotope ratio method for measurement of cholesterol absorption in man. J Lipid Res. 1978;19:82–93.
McNamara DJ, Kolb R, Parker TS, et al. Heterogeneity of cholesterol homeostasis in man. Response to changes in dietary fat quality and cholesterol quantity. J Clin Invest. 1987;79:1729–39.
Samuel P, McNamara DJ, Ahrens Jr EH, Crouse JR, Parker T. Further validation of the plasma isotope ratio method for measurement of cholesterol absorption in man. J Lipid Res. 1982;23:480–9.
Grundy SM, Mok HY. Determination of cholesterol absorption in man by intestinal perfusion. J Lipid Res. 1977;18:263–71.
•• Altmann SW, Davis Jr HR, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201–4. This study demonstrated that intestinal protein NPC1L1 mediates cholesterol absorption.
Davis Jr HR, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem. 2004;279:33586–92.
Cohen JC, Pertsemlidis A, Fahmi S, et al. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci U S A. 2006;103(103):1810–5.
Grundy SM, Metzger AL. A physiological method for estimation of hepatic secretion of biliary lipids in man. Gastroenterology. 1972;62:1200–17.
Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol. 1994;5:102–9.
Hanson J. John Cornforth (1917–2013). Nature. 2014;506:35.
Sharpe LJ, Brown AJ. Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). J Biol Chem. 2013;288:18707–15.
Gould RG, Taylor CB, Hagerma JS, Warner I, Campbell DJ. Cholesterol metabolism. I. Effect of dietary cholesterol on the synthesis of cholesterol in dog tissue in vitro. J Biol Chem. 1953;201:519–28.
Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34:1637–59.
Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–30.
Shimomura I, Bashmakov Y, Shimano H, Horton JD, Goldstein JL, Brown MS. Cholesterol feeding reduces nuclear forms of sterol regulatory element binding proteins in hamster liver. Proc Natl Acad Sci U S A. 1997;94:12354–9.
Pertsemlidis D, Kirchman EH, Ahrens Jr EH. Regulation of cholesterol metabolism in the dog. I. Effects of complete bile diversion and of cholesterol feeding on absorption, synthesis, accumulation, and excretion rates measured during life. J Clin Invest. 1973;52:2353–67.
Dietschy JM, Wilson JD. Regulation of cholesterol metabolism. 3. N Engl J Med. 1970;282:1241–9.
Cohen BI, Matoba N, Mosbach EH, McSherry CK. Dietary induction of cholesterol gallstones in hamsters from three different sources. Lipids. 1989;24:151–6.
Parks JS, Wilson MD, Johnson FL, Rudel LL. Fish oil decreases hepatic cholesteryl ester secretion but not apoB secretion in African green monkeys. J Lipid Res. 1989;30:1535–44.
Huettinger M, Corbett JR, Schneider WJ, Willerson JT, Brown MS, Goldstein JL. Imaging of hepatic low density lipoprotein receptors by radionuclide scintiscanning in vivo. Proc Natl Acad Sci U S A. 1984;81:7599–603.
Dietschy JM, Woollett LA, Spady DK. The interaction of dietary cholesterol and specific fatty acids in the regulation of LDL receptor activity and plasma LDL-cholesterol concentrations. Ann N Y Acad Sci. 1993;676:11–26.
Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29:431–8.
•• Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. This meta-analysis shows that for every 1% change in LDL-Cholesterol levels, there is an approximate 1% change in risk for cardiovascular disease over 5 years.
•• Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631–9. This study showed that for every 1% change in LDL-cholesterol over a lifetime the risk for atherosclerotic cardiovascular disease is changed by approximately 3%.
Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473–85.
Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol. 2002;13:461–70.
Proctor SD, Mamo JC. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol. 2003;23:1595–600.
Tall AR, Small DM, Atkinson D, Rudel LL. Studies on the structure of low density lipoproteins isolated from Macaca fascicularis fed an atherogenic diet. J Clin Invest. 1978;62:1354–63.
Mahley RW, Innerarity TL, Brown MS, Ho YK, Goldstein JL. Cholesteryl ester synthesis in macrophages: stimulation by beta-very low density lipoproteins from cholesterol-fed animals of several species. J Lipid Res. 1980;21:970–80.
Castro GR, Fielding CJ. Effects of postprandial lipemia on plasma cholesterol metabolism. J Clin Invest. 1985;75:874–82.
Beynen AC, Katan MB. Effect of egg yolk feeding on the concentration and composition of serum lipoproteins in man. Atherosclerosis. 1985;54:157–66.
Weggemans RM, Zock PL, Katan MB. Dietary cholesterol from eggs increases the ratio of total cholesterol to high-density lipoprotein cholesterol in humans: a meta-analysis. Am J Clin Nutr. 2001;73:885–91.
Shekelle RB, Stamler J. Dietary cholesterol and ischaemic heart disease. Lancet. 1989;1:1177–9.
Katan MB, Grundy SM. Jones P, Law M, Miettinen T, Paoletti R; Stresa Workshop Participants. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003;78:965–78.
Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102:8132–7.
Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:1943–8.
Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092–7. Erratum in: Am J Cardiol. 2003;91:1399.
•• Myocardial Infarction Genetics Consortium Investigators, Stitziel NO, Won HH, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371:2072–82. This study demonstrated that inactiving mutations of NPC1L reduces risk for coronary heart disease by approximately 46%.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Scott M. Grundy declares no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Nutrition
Rights and permissions
About this article
Cite this article
Grundy, S.M. Does Dietary Cholesterol Matter?. Curr Atheroscler Rep 18, 68 (2016). https://doi.org/10.1007/s11883-016-0615-0
Published:
DOI: https://doi.org/10.1007/s11883-016-0615-0
Keywords
- Dietary cholesterol
- Cholesterol absorption
- Eggs
- Low-density lipoproteins
- Plant sterols
- Plant stanols
- Ezetimibe